Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
14.93
Nov 06 • 3:59 PM ET Dollar change+0.44 Percentage change(3.04%)
Aftermarket Close
14.94
Aftermarket • 6:48 PM ET Dollar change+0.01 Percentage change(0.07%)
Index
RUT
Market Cap
518.05M
Enterprise Value
424.61M
Income
0.53M
Sales
95.42M
Book/sh
3.50
Cash/sh
2.76
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
156
IPO
Oct 23, 2001
P/E
2447.54
Forward P/E
-
PEG
-
P/S
5.43
P/B
4.27
P/C
5.40
P/FCF
29.59
EV/EBITDA
-
EV/Sales
4.45
Quick Ratio
8.95
Current Ratio
9.83
Debt/Eq
0.02
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
0.01
EPS next Y
-0.06
EPS next Q
-0.09
EPS this Y
-358.03%
EPS next Y
66.51%
EPS next 5Y
37.00%
EPS past 3/5Y
- -
Sales past 3/5Y
215.30% 120.21%
EPS Y/Y TTM
-76.27%
Sales Y/Y TTM
35.85%
EPS Q/Q
0.15%
Sales Q/Q
20.60%
Insider Own
7.49%
Insider Trans
0.00%
Inst Own
60.23%
Inst Trans
2.25%
ROA
0.42%
ROE
0.47%
ROIC
0.43%
Gross Margin
87.05%
Oper. Margin
-1.90%
Profit Margin
0.56%
SMA20
1.80%
SMA50
-3.35%
SMA200
19.96%
Trades
Shs Outstand
34.64M
Shs Float
32.10M
52W High
17.42 -14.29%
52W Low
8.12 83.87%
Volatility
4.20% 3.73%
ATR (14)
0.58
RSI (14)
50.78
Beta
0.59
Rel Volume
1.51
Avg Volume
460.64K
Volume
696,865
Perf Week
6.34%
Perf Month
-0.73%
Perf Quarter
-10.44%
Perf Half Y
30.05%
Perf YTD
47.82%
Perf Year
72.80%
Perf 3Y
369.50%
Perf 5Y
27.39%
Perf 10Y
-100.00%
Prev Close
14.49
Price
14.93
Change %
3.04%
Consensus
Strong Buy
Avg. Price Target
$24.50
Implied Upside
+64.1%
Analysts6incl. previous ratings
Rating Distribution6 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 28, 2024Initiated
CCraig Hallum
Buy$18+20.6%
May 14, 2024Initiated
SStephens
Overweight$25+67.4%
Jul 26, 2022Resumed
CCanaccord Genuity
Buy$17+13.9%
Dec 10, 2021Initiated
HH.C. Wainwright
Buy$25+67.4%
Mar 09, 2021Initiated
CCanaccord Genuity
Buy$24+60.8%
Jan 05, 2021Initiated
BBTIG Research
Buy$23+54.1%
Jun 01, 2020Initiated
LLaidlaw
Buy$19+27.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pennell SandraChief Financial OfficerMar 06 '26Buy9.045,53350,01877,018Mar 06 04:22 PM
Sylvester John RichardDirectorNov 21 '25Buy8.894,38638,99214,936Nov 25 04:15 PM
MICHEL GERARD JCHIEF EXECUTIVE OFFICERNov 11 '25Buy8.5311,50098,049330,834Nov 13 11:53 AM
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.
MSMr. Gerard J. Michel MBA
Chief Operating OfficerDr. Martha S. Rook Ph.D.
M.Sc.Dr. Vojislav Vukovic M.D.
Chief Financial OfficerMs. Sandra Pennell CPA
General CounselMr. David Hoffman J.D.